Mallardo, Domenico

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

Coutzac, C., Jouniaux, J.-M., Paci, A., Schmidt, J., Mallardo, D., Seck, A., Asvatourian, V., Cassard, L., Saulnier, P., Lacroix, L., et al. (2020) · Nature Communications

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 513

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

Capone, M., Giannarelli, D., Mallardo, D., Madonna, G., Festino, L., Grimaldi, A. M., Vanella, V., Simeone, E., Paone, M., Palmieri, G., et al. (2018) · Journal for ImmunoTherapy of Cancer

Inflammatory Biomarkers in Disease PrognosisCancer Immunotherapy and Biomarkers

Cited by 497

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Cortellini, A., Tucci, M., Adamo, V., Stucci, L. S., Russo, A., Tanda, E. T., Spagnolo, F., Rastelli, F., Bisonni, R., Santini, D., et al. (2020) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis

Cited by 275

Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients

Wistuba-Hamprecht, K., Martens, A., Heubach, F., Romano, E., Geukes Foppen, M., Yuan, J., Postow, M., Wong, P., Mallardo, D., Schilling, B., et al. (2017) · European Journal of Cancer

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 108

Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients

Macandog, A. D. G., Catozzi, C., Capone, M., Nabinejad, A., Nanaware, P. P., Liu, S., Vinjamuri, S., Stunnenberg, J. A., Galiè, S., Jodice, M. G., et al. (2024) · Cell Host & Microbe

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 40

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

Ascierto, P. A., Capone, M., Grimaldi, A. M., Mallardo, D., Simeone, E., Madonna, G., Roder, H., Meyer, K., Asmellash, S., Oliveira, C., et al. (2019) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways

Cited by 30